Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medtronic Inc Secures Approval Of First Artificial Pancreas Device System With Threshold Suspend Automation


Friday, 27 Sep 2013 08:30am EDT 

Medtronic, Inc announced the U.S. Food and Drug Administration (FDA) approval of the MiniMed 530G with Enlite, an artificial pancreas system with Threshold Suspend automation for people with diabetes. The MiniMed 530G system incorporates the new Enlite sensor, Medtronic's accurate continuous glucose sensor with a 31% improvement in overall accuracy from the previous generation. The MiniMed 530G system was approved for use by people with diabetes ages 16 and older. Medtronic will conduct a post-approval study including children ages two and older. The Enlite sensor can be worn for six days. 

Company Quote

62.9
-0.38 -0.60%
25 Jul 2014